Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting

被引:0
作者
Ferrari, Fiorenza [1 ]
Sodi, Federico [1 ,2 ]
Madotto, Fabiana [1 ]
Carlesso, Eleonora [2 ]
Florio, Gaetano [1 ]
Pelliccia, Maria Rosa [2 ]
Laquintana, Dario [3 ]
Bisesti, Alberto [3 ]
Piatti, Alessandra [4 ]
Letzgus, Matteo [4 ]
Tiwana, Navpreet [4 ]
Jachetti, Alessandro [5 ]
Mancarella, Marta [5 ]
Cereda, Danilo [6 ]
Leoni, Olivia [6 ]
Borriello, Catia Rosanna [6 ]
Chiappa, Laura [7 ]
Sottocorno, Marcello [8 ]
Costantino, Giorgio [5 ,9 ]
Zanella, Alberto [1 ,2 ]
Grasselli, Giacomo [1 ,2 ]
机构
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dipartimento Area Emergenza Urgenza, Milan, Italy
[2] Univ Milan, Dept Pathophysiol & Transplantat, Padiglione Litta, Milan, Italy
[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Direz Aziendale Profess Sanit, Milan, Italy
[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Direz Med Presidio, Milan, Italy
[5] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Emergency Dept, Milan, Italy
[6] Gen Directorate Hlth, Milan, Lombardy Region, Italy
[7] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Direz Sanitaria, Milan, Italy
[8] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hosp Pharm, Milan, Italy
[9] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
关键词
Mass vaccination; Immunization programs; COVID-19; vaccines; Early medical intervention; COVID-19; VACCINE;
D O I
10.1007/s11739-024-03641-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
During COVID-19 pandemic, vaccination has been strongly recommended and advocated to prevent COVID-19 infection and adverse outcomes, particularly among at-risk populations. The vaccination against SARS-CoV-2 (COVAC) occurred at off-site locations capable of accommodating large crowds, distinct from the hospital setting, where a team of intensivists, emergency physicians, and nurses, ensuring prompt medical attention (medical occurrences, MO) in cases of adverse event following immunization. Our aims were to estimate the incidence of MO, and to assess its association with demographics, and vaccine characteristics. Our retrospective cohort study included all subject aged 12 years and older who received vaccinations at two large out-of-hospital vaccination hubs (Fiera Milano City, Palazzo delle Scintille), between April 12th and August 31st, 2021. Nine hundred and ninety-five thousand and twenty-eight vaccinations were administrated. MOs incidence rate was 278/100,000 doses (95% confidence interval (CI) 268-289). Most MOs were mild (86.27%) and mainly observed in subjects who received the Comirnaty vaccine; 92 MOs (3.32%) were severe and mostly occurred in recipients of the Vaxzeria vaccine. The incidence rate for hospital transfers following vaccination was 4.7/100,000 doses (95% CI 3.5-6.2) and any level of anaphylaxis occurred in 0.4 cases per 100,000 administrated doses (95% CI 0.3.-0.7). Sex, age, type of vaccine and first dose were associated with incidence of MO. Our results showed a low incidence rate in MOs after COVAC, mainly mild and support the feasibility, effectiveness and safety of vaccinations administered in hubs with a dedicated SEU located outside of the hospital setting.
引用
收藏
页码:1593 / 1604
页数:12
相关论文
共 40 条
  • [1] Agenzia Italiana del Farmaco (AIFA), Vaccini COVID-19
  • [2] Post-vaccination survey for monitoring the side effects associated with COVID-19 vaccines among healthcare professionals of Jazan province, Saudi Arabia
    Ahsan, Waquar
    Syed, Nabeel K.
    Alsraeya, Aseel A.
    Alhazmi, Hassan A.
    Najmi, Asim
    Al Bratty, Mohammed
    Javed, Shamama
    Makeen, Hafiz A.
    Meraya, Abdulkarim M.
    Albarraq, Ahmed A.
    Alqahtani, Saad S.
    [J]. SAUDI MEDICAL JOURNAL, 2021, 42 (12) : 1341 - 1352
  • [3] AIFA, 2021, Nono rapporto AIFA sulla sorveglianza dei vaccini COVID-19
  • [4] Efficacy and Short-Term Safety of COVID-19 Vaccines: A Cross-Sectional Study on Vaccinated People in the UAE
    AlHamaidah, Mustafa Ameen
    Noureldin, Noora
    Yehia, Adham
    Alani, Ibrahim
    Al-Qussain, Abdelaziz
    Abdou, Osama
    Ashames, Akram
    Kharaba, Zelal
    [J]. VACCINES, 2022, 10 (12)
  • [5] Materials for non-viral intracellular delivery of messenger RNA therapeutics
    Kauffman, Kevin J.
    Webber, Matthew J.
    Anderson, Daniel G.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2016, 240 : 227 - 234
  • [6] The Coronavirus Disease 2019 (COVID-19) Pandemic
    Baloch, Saira
    Baloch, Mohsin Ali
    Zheng, Tianli
    Pei, Xiaofang
    [J]. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2020, 250 (04) : 271 - 278
  • [7] Brighton Collaboration Anaphylaxis Working Group, 2021, Anaphylaxis: case definition companion guide
  • [8] Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines
    Caballero, M. L.
    Quirce, S.
    [J]. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2021, 31 (01) : 92 - 93
  • [9] Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study
    El-Shitany, Nagla A.
    Harakeh, Steve
    Badr-Eldin, Shaimaa M.
    Bagher, Amina M.
    Eid, Basma
    Almukadi, Haifa
    Alghamdi, Badrah S.
    Alahmadi, Ahlam A.
    Hassan, Nibal A.
    Sindi, Nariman
    Alghamdi, Samar A.
    Almohaimeed, Hailah M.
    Mohammedsaleh, Zuhair M.
    Al-Shaikh, Turki M.
    Almuhayawi, Mohammed S.
    Ali, Soad S.
    El-Hamamsy, Manal
    [J]. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 1389 - 1401
  • [10] European Medicines Agency (EMA), 2017, Guidelines on good pharmacovigilance practices (GVP)